New drug shows promise for Tough-to-Treat prostate cancer
NCT ID NCT04702737
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a drug called Tarlatamab in 41 men with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer. The main goal was to check the drug's safety and find the best dose. The drug works by helping the body's immune cells recognize and attack cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tarlatamab (also called AMG 757), a drug that helps immune cells attack cancer cells
What this could lead to
If successful, this could lead to a new treatment option for men with a rare and aggressive form of prostate cancer that currently has few options.
What could go wrong
This is an early phase 1 trial with only 41 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects may be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Community Health Network MD Anderson Cancer Center - North
Indianapolis, Indiana, 46250, United States
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Keio University Hospital
Shinjuku-ku, Tokyo, 160-8582, Japan
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Medizinische Universitaet Graz
Graz, 8036, Austria
-
Ordensklinikum Linz Elisabethinen
Linz, 4020, Austria
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
University of California at San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27103, United States
-
Washington University
St Louis, Missouri, 63110-1093, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States